Form 4: Director Acquires 100,000 Shares in Drugs Made In America Acquisition Corp.

Catherine Do, a director of Drugs Made In America Acquisition Corp., acquired 100,000 ordinary shares from the company's sponsor for no consideration.

Summary

• Catherine Do, a director at Drugs Made In America Acquisition Corp., acquired 100,000 ordinary shares.
• The shares were acquired from Drugs Made In America Acquisition LLC, the company's sponsor.
• The acquisition was made on January 29, 2025.
• No consideration was paid for the shares.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of a share acquisition by a director. It does not contain any information that would indicate a positive or negative sentiment.

Positives

• A director increasing their stake in the company can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders reporting changes in their beneficial ownership of company stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The acquisition of shares by a director is a common occurrence and is not unusual in the context of corporate governance.
• Similar filings are made by directors and officers of all publicly traded companies, such as those listed on the NYSE and NASDAQ.

Related Party Transactions

• The shares were acquired from Drugs Made In America Acquisition LLC, the Issuer's sponsor, which is a related party.

Stakeholder Impact

• The acquisition of shares by a director may have a minor positive impact on shareholder confidence.

Key Dates

Keywords

share acquisition, director, beneficial ownership, ordinary shares, Drugs Made In America Acquisition Corp., DMAA